ORGO
Price
$1.77
Change
+$0.01 (+0.57%)
Updated
Aug 14, 01:15 PM (EDT)
Capitalization
226.47M
83 days until earnings call
Intraday BUY SELL Signals
PCRX
Price
$23.11
Change
-$0.07 (-0.30%)
Updated
Aug 14, 01:19 PM (EDT)
Capitalization
924M
76 days until earnings call
Intraday BUY SELL Signals
Interact to see
Advertisement

ORGO vs PCRX

ORGO vs PCRX Comparison Chart in %
loading
loading
View a ticker or compare two or three
VS
ORGO vs. PCRX commentary
Aug 14, 2026

To compare these two companies we present long-term analysis, their fundamental ratings and make comparative short-term technical analysis which are presented below. The conclusion is ORGO is a Hold and PCRX is a Hold.

Interact to see
Advertisement
COMPARISON
Comparison
Aug 14, 2026
Stock price -- (ORGO: $1.76 vs. PCRX: $23.18)
Brand notoriety: ORGO and PCRX are both not notable
Both companies represent the Pharmaceuticals: Generic industry
Current volume relative to the 65-day Moving Average: ORGO: 86% vs. PCRX: 92%
Market capitalization -- ORGO: $226.47M vs. PCRX: $924M
ORGO [@Pharmaceuticals: Generic] is valued at $226.47M. PCRX’s [@Pharmaceuticals: Generic] market capitalization is $924M. The market cap for tickers in the [@Pharmaceuticals: Generic] industry ranges from $63.66B to $0. The average market capitalization across the [@Pharmaceuticals: Generic] industry is $4B.

Long-Term Analysis

It is best to consider a long-term outlook for a ticker by using Fundamental Analysis (FA) ratings. The rating of 1 to 100, where 1 is best and 100 is worst, is divided into thirds. The first third (a green rating of 1-33) indicates that the ticker is undervalued; the second third (a grey number between 34 and 66) means that the ticker is valued fairly; and the last third (red number of 67 to 100) reflects that the ticker is undervalued. We use an FA Score to show how many ratings show the ticker to be undervalued (green) or overvalued (red).

ORGO’s FA Score shows that 0 FA rating(s) are green whilePCRX’s FA Score has 1 green FA rating(s).

  • ORGO’s FA Score: 0 green, 5 red.
  • PCRX’s FA Score: 1 green, 4 red.
According to our system of comparison, PCRX is a better buy in the long-term than ORGO.

Short-Term Analysis

It is best to consider a short-term outlook for a ticker by using Technical Analysis (TA) indicators. We use Odds of Success as the percentage of outcomes which confirm successful trade signals in the past.

If the Odds of Success (the likelihood of the continuation of a trend) for each indicator are greater than 50%, then the generated signal is confirmed. A green percentage from 90% to 51% indicates that the ticker is in a bullish trend. A red percentage from 90% - 51% indicates that the ticker is in a bearish trend. All grey percentages are below 50% and are considered not to confirm the trend signal.

ORGO’s TA Score shows that 5 TA indicator(s) are bullish while PCRX’s TA Score has 3 bullish TA indicator(s).

  • ORGO’s TA Score: 5 bullish, 5 bearish.
  • PCRX’s TA Score: 3 bullish, 6 bearish.
According to our system of comparison, ORGO is a better buy in the short-term than PCRX.

Price Growth

ORGO (@Pharmaceuticals: Generic) experienced а -26.97% price change this week, while PCRX (@Pharmaceuticals: Generic) price change was -9.38% for the same time period.

The average weekly price growth across all stocks in the @Pharmaceuticals: Generic industry was -0.05%. For the same industry, the average monthly price growth was +2.34%, and the average quarterly price growth was +28.00%.

Reported Earning Dates

ORGO is expected to report earnings on Nov 05, 2026.

PCRX is expected to report earnings on Oct 29, 2026.

Industries' Descriptions

@Pharmaceuticals: Generic (-0.05% weekly)

A generic drug contains the same chemical substance as a drug that was originally protected by patents. Generic drugs are generally sold at cheaper price points, compared to name-brand pharmaceuticals, after patents for the more expensive drugs lapse. The generic drug industry has created a major market, thanks to the lower pricing. According to the Center for Justice and Democracy at New York Law School, 80 percent of all drugs prescribed are generic, and generic drugs are chosen 94 percent of the time when they are available. But their manufacturers must be able to prove to the FDA that they can be effective substitutes for the original drugs. Some of the major generic drug makers include Zoetis, Inc., Allergan plc and Mylan N.V.

SUMMARIES
Loading...
FUNDAMENTALS
Fundamentals
PCRX($924M) has a higher market cap than ORGO($226M). PCRX has higher P/E ratio than ORGO: PCRX (66.23) vs ORGO (16.87). PCRX YTD gains are higher at: -10.433 vs. ORGO (-66.023). PCRX has higher annual earnings (EBITDA): 118M vs. ORGO (40.2M). PCRX has more cash in the bank: 202M vs. ORGO (91.4M). ORGO has less debt than PCRX: ORGO (70.9M) vs PCRX (411M). PCRX has higher revenues than ORGO: PCRX (735M) vs ORGO (513M).
ORGOPCRXORGO / PCRX
Capitalization226M924M24%
EBITDA40.2M118M34%
Gain YTD-66.023-10.433633%
P/E Ratio16.8766.2325%
Revenue513M735M70%
Total Cash91.4M202M45%
Total Debt70.9M411M17%
FUNDAMENTALS RATINGS
ORGO vs PCRX: Fundamental Ratings
ORGO
PCRX
OUTLOOK RATING
1..100
775
VALUATION
overvalued / fair valued / undervalued
1..100
43
Fair valued
63
Fair valued
PROFIT vs RISK RATING
1..100
100100
SMR RATING
1..100
9491
PRICE GROWTH RATING
1..100
8859
P/E GROWTH RATING
1..100
6218
SEASONALITY SCORE
1..100
50n/a

Tickeron ratings are formulated such that a rating of 1 designates the most successful stocks in a given industry, while a rating of 100 points to the least successful stocks for that industry.

ORGO's Valuation (43) in the Financial Conglomerates industry is in the same range as PCRX (63) in the Pharmaceuticals Other industry. This means that ORGO’s stock grew similarly to PCRX’s over the last 12 months.

ORGO's Profit vs Risk Rating (100) in the Financial Conglomerates industry is in the same range as PCRX (100) in the Pharmaceuticals Other industry. This means that ORGO’s stock grew similarly to PCRX’s over the last 12 months.

PCRX's SMR Rating (91) in the Pharmaceuticals Other industry is in the same range as ORGO (94) in the Financial Conglomerates industry. This means that PCRX’s stock grew similarly to ORGO’s over the last 12 months.

PCRX's Price Growth Rating (59) in the Pharmaceuticals Other industry is in the same range as ORGO (88) in the Financial Conglomerates industry. This means that PCRX’s stock grew similarly to ORGO’s over the last 12 months.

PCRX's P/E Growth Rating (18) in the Pharmaceuticals Other industry is somewhat better than the same rating for ORGO (62) in the Financial Conglomerates industry. This means that PCRX’s stock grew somewhat faster than ORGO’s over the last 12 months.

TECHNICAL ANALYSIS
Technical Analysis
ORGOPCRX
RSI
ODDS (%)
Bullish Trend 2 days ago
77%
Bearish Trend 2 days ago
77%
Stochastic
ODDS (%)
Bullish Trend 2 days ago
82%
Bullish Trend 2 days ago
73%
Momentum
ODDS (%)
Bearish Trend 2 days ago
89%
Bearish Trend 2 days ago
75%
MACD
ODDS (%)
Bearish Trend 2 days ago
88%
Bearish Trend 2 days ago
74%
TrendWeek
ODDS (%)
Bearish Trend 2 days ago
90%
Bearish Trend 2 days ago
76%
TrendMonth
ODDS (%)
Bearish Trend 2 days ago
89%
Bearish Trend 2 days ago
78%
Advances
ODDS (%)
Bullish Trend 25 days ago
76%
Bullish Trend 11 days ago
71%
Declines
ODDS (%)
Bearish Trend 2 days ago
88%
Bearish Trend 2 days ago
76%
BollingerBands
ODDS (%)
Bullish Trend 2 days ago
81%
Bearish Trend 2 days ago
78%
Aroon
ODDS (%)
Bullish Trend 4 days ago
71%
Bullish Trend 2 days ago
68%
View a ticker or compare two or three
Interact to see
Advertisement
ORGO
Daily Signal:
Gain/Loss:
PCRX
Daily Signal:
Gain/Loss:
Interesting Tickers
1D
1W
1M
1Q
6M
1Y
5Y
1 Day
MFs / NAMEPrice $Chg $Chg %
LICYX21.52N/A
N/A
Lord Abbett International Equity I
PABVX18.10N/A
N/A
Principal MidCap Value I R5
SSEIX14.41N/A
N/A
SouthernSun U.S. Equity, I
JEMWX53.22N/A
N/A
JPMorgan Emerging Markets Equity R6
MVGIX18.68N/A
N/A
MFS Low Volatility Global Equity I

ORGO and

Correlation & Price change

A.I.dvisor indicates that over the last year, ORGO has been loosely correlated with ANIK. These tickers have moved in lockstep 36% of the time. This A.I.-generated data suggests there is some statistical probability that if ORGO jumps, then ANIK could also see price increases.

1D
1W
1M
1Q
6M
1Y
5Y
Ticker /
NAME
Correlation
To ORGO
1D Price
Change %
ORGO100%
-2.76%
ANIK - ORGO
36%
Loosely correlated
-3.90%
PRGO - ORGO
31%
Poorly correlated
+1.10%
ACET - ORGO
29%
Poorly correlated
N/A
AMPH - ORGO
25%
Poorly correlated
+1.00%
PCRX - ORGO
24%
Poorly correlated
-2.19%
More

PCRX and

Correlation & Price change

A.I.dvisor tells us that PCRX and ELAN have been poorly correlated (+32% of the time) for the last year. This A.I.-generated data suggests there is low statistical probability that PCRX and ELAN's prices will move in lockstep.

1D
1W
1M
1Q
6M
1Y
5Y
Ticker /
NAME
Correlation
To PCRX
1D Price
Change %
PCRX100%
-2.19%
ELAN - PCRX
32%
Poorly correlated
+1.72%
XERS - PCRX
29%
Poorly correlated
-1.88%
SXTC - PCRX
28%
Poorly correlated
N/A
COLL - PCRX
27%
Poorly correlated
+9.53%
ACET - PCRX
27%
Poorly correlated
N/A
More